MMP1

Summary

MMP1 (matrix metallopeptidase 1, HGNC:7155) is a protein-coding gene on chromosome 11q22.2, encoding Interstitial collagenase (P03956). Cleaves collagens of types I, II, and III at one site in the helical domain. In precision oncology, MMP1 Overexpression is associated with resistance to Sacituzumab Govitecan in Estrogen-receptor Positive Breast Cancer (CIViC Level D).

This gene encodes a member of the peptidase M10 family of matrix metalloproteinases (MMPs). Proteins in this family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. The encoded preproprotein is proteolytically processed to generate the mature protease. This secreted protease breaks down the interstitial collagens, including types I, II, and III. The gene is part of a cluster of MMP genes on chromosome 11. Mutations in this gene are associated with chronic obstructive pulmonary disease (COPD). Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.

Source: NCBI Gene 4312 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 146 total
• Phenotypes (HPO): 58
• Druggable target: yes — 21 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 1 curated variant–drug association
• MANE Select transcript: NM_002421

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7155
Approved symbol	MMP1
Name	matrix metallopeptidase 1
Location	11q22.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000196611
Ensembl biotype	protein_coding
OMIM	120353
Entrez	4312

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding_CDS_not_defined, 1 protein_coding, 1 retained_intron

ENST00000315274, ENST00000680179, ENST00000681445, ENST00000681643

RefSeq mRNA: 2 — MANE Select: NM_002421 NM_001145938, NM_002421

CCDS: CCDS8322

Canonical transcript exons

ENST00000315274 — 10 exons

Exon	Start	End
ENSE00000993183	102795174	102795291
ENSE00000993195	102792605	102792738
ENSE00000993197	102795452	102795607
ENSE00000993199	102791333	102791495
ENSE00000993204	102790703	102790806
ENSE00000993211	102797256	102797500
ENSE00000993213	102797014	102797162
ENSE00001105440	102796664	102796789
ENSE00001234609	102797988	102798160
ENSE00001234621	102789919	102790521

Expression profiles

Bgee: expression breadth ubiquitous, 172 present calls, max score 99.09.

FANTOM5 (CAGE): breadth broad, TPM avg 239.1385 / max 18368.5720, expressed in 879 samples.

FANTOM5 promoters (24 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122018	231.0513	856
122001	3.1155	283
121998	0.7959	180
121995	0.5200	164
122009	0.4695	162
122012	0.4472	170
122008	0.4334	130
122007	0.2731	109
122011	0.2674	114
122015	0.2650	122

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	99.09	gold quality
pancreatic ductal cell	CL:0002079	98.93	gold quality
islet of Langerhans	UBERON:0000006	98.21	gold quality
cartilage tissue	UBERON:0002418	98.20	gold quality
type B pancreatic cell	CL:0000169	97.71	gold quality
synovial membrane of synovial joint	UBERON:0002018	97.06	gold quality
gall bladder	UBERON:0002110	94.66	gold quality
stromal cell of endometrium	CL:0002255	90.21	gold quality
amniotic fluid	UBERON:0000173	85.31	gold quality
pylorus	UBERON:0001166	83.59	gold quality
decidua	UBERON:0002450	83.35	gold quality
mucosa of urinary bladder	UBERON:0001259	81.56	gold quality
duodenum	UBERON:0002114	81.39	gold quality
jejunal mucosa	UBERON:0000399	79.93	gold quality
palpebral conjunctiva	UBERON:0001812	78.93	gold quality
vermiform appendix	UBERON:0001154	78.27	gold quality
rectum	UBERON:0001052	76.63	gold quality
body of stomach	UBERON:0001161	75.96	gold quality
caecum	UBERON:0001153	75.86	gold quality
mucosa of sigmoid colon	UBERON:0004993	75.50	gold quality
visceral pleura	UBERON:0002401	74.84	gold quality
periodontal ligament	UBERON:0008266	74.37	silver quality
stomach	UBERON:0000945	72.88	gold quality
nasal cavity epithelium	UBERON:0005384	72.01	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.10	gold quality
colonic mucosa	UBERON:0000317	70.80	gold quality
colonic epithelium	UBERON:0000397	69.98	gold quality
placenta	UBERON:0001987	68.08	gold quality
pancreas	UBERON:0001264	68.00	gold quality
jejunum	UBERON:0002115	67.73	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-10	yes	2840.46
E-MTAB-6308	yes	953.77
E-MTAB-5061	yes	5.93
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, AP1, AR, ATF2, ATF3, BACH1, BATF3, BCL3, CEBPA, CEBPB, CEBPG, CITED2, COP1, CREB1, CTNNB1, EGR1, EHF, ELF2, ERG, ESR1, ESR2, ETS1, ETS2, ETV1, ETV2, ETV3, ETV4, ETV7, EWSR1, FBN1, FLI1, FOS, FOSL1, FOXN1, FOXO1, FOXO3, GATA3, HIF1A, HOPX, HR

miRNA regulators (miRDB)

38 targeting MMP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7F-5P	99.98	72.56	1784
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3176	99.25	64.35	954
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-5190	99.15	67.76	1234
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-5094	98.63	67.11	1062
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-3136-5P	98.53	67.68	793
HSA-MIR-4439	98.53	67.53	793
HSA-MIR-326	98.25	66.44	1565

Literature-anchored findings (GeneRIF, showing 40)

• Patients with detectable concentrations of urinary MMP-1 had higher rates of disease progression and death from bladder cancer than patients with undetectable urinary MMP-1. (PMID:11705862)
• members of the forkhead family of transcription factors play a role in regulation of the collagenase promoter and increased activity of forkhead transcription factors underlie the increase in collagenase expression observed during replicative senescence (PMID:11751876)
• 17beta-estradiol represses MMP-1 synthesis, and this effect may contribute to its action on the inhibition of bone resorption (PMID:11762702)
• role in degradation of extracellular matrix and joint destruction (PMID:11831026)
• induction in fibroblasts by basic calcium phosphate crystals (PMID:11836255)
• These data suggest that polymorphisms in the MMP1 and MMP12 genes, but not MMP9, are either causative factors in smoking-related lung injury or are in linkage disequilibrium with causative polymorphisms (PMID:11875051)
• Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. (PMID:11918701)
• in the late healing period of radiation-impaired wounds, increased expression of MMP1 may be related to overdegradation of matrixes and difficulty in granulation tissue formation (PMID:11934016)
• A newly identified single nucleotide polymorphism at position -519 in the promoter region of the MMP-1 gene is reported. This polymorphism consists in a guanine to adenine substitution. A linkage between polymorphisms -519A/G and -1607 1G/2G was studied. (PMID:12005449)
• Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells (PMID:12009332)
• Accessory elements, flanking DNA sequence, and promoter context play key roles in determining the efficacy of insulin and phorbol ester signaling through the enzyme motifs (PMID:12032154)
• destruction of the surrounding matrix by endometriosis might be caused by various MMPs, which are mainly produced in stromal cells. (PMID:12034345)
• Oxidized low-density and high-density lipoproteins regulate the production by activated monocytes (PMID:12050187)
• lack of expression in Ewing sarcoma may be due to loss of accessibility of regulatory element to the specific fusion protein in vivo (PMID:12054564)
• Activation of p38 alpha MAPK enhances its expression by mRNA stabilization (PMID:12060661)
• Activation of protein kinase CK2 is an early step in the ultraviolet B-mediated increase in interstitial collagenase (matrix metalloproteinase-1; MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. (PMID:12071839)
• Results demonstrate that generation of the 44-kDa membrane type-1 matrix metalloproteinase (MT1-MMP) autolysis product regulates collagenolytic activity and subsequent invasive potential. (PMID:12145314)
• keratinocyte-fibroblast interactions are mediated by multiple stimulating agents acting on specific receptors to induce signalling through different mitogen-activated protein kinase pathways leading to altered expression of key biological functions. (PMID:12177784)
• Association of a polymorphism of the matrix metalloproteinase-1 gene with bone mineral density.Bone density for the distal radius was significantly lower in postmenopausal women with the GG/GG genotype. (PMID:12225803)
• MMP1 may play a pivotal role in the formation of capillarylike tubular structures in a collagen-containing fibrin matrix in vitro and may be involved in angiogenesis in a fibrinous exudate in vivo. (PMID:12393408)
• Genotyping was carried out using PCR-RFLP and direct sequencing. In the MMP-1 gene polymorphism, the frequency of the 2G/2G genotype that is associated with higher enzyme activity was significantly increased in colorectal cancer patients (PMID:12432557)
• viral LMP1 and Zta proteins regulate the expression and activity of MMP-1; first evidence that viral proteins are capable of regulating MMP-1 and clues for the role of EBV in nasopharyngeal carcinoma progression (PMID:12517806)
• A novel promoter element was detected in the human MMP1 gene, and the inflammation-responsive transcription factor SAF-1 was found to interact with it in osteoarthritis (PMID:12528113)
• a polymorphism in the promoter region is associated with the severe chronic periodontitis phenotype in non-smokers (PMID:12622858)
• expression and regulation by intestinal myofibroblasts in inflammatory bowel disease (PMID:12651627)
• catalytic activity on the cell surface is regulated through a vacuolar H(+)-ATPase-dependent degradation process (PMID:12667140)
• MMP-1 induces progressive adult-onset emphysema by the selective degradation of type III collagen within the alveolar wall. (PMID:12676763)
• Gene expression for MMP-1 after UVA1 irradiation was induced in all fibroblasts, but the induction rate was greater in systemic sclerosis fibroblasts than in normal ones. (PMID:12692352)
• MMP1 has a role in tumor invasion [review] (PMID:12706853)
• MT1-MMP-catalyzed release of beta-amyloid precursor protein leads to reduction of the extracellular matrix-associated gelatinase A inhibitor, sAPP, thus making it feasible for gelatinase A to exert proteolytic activity only near its activator, MT1-MMP (PMID:12767235)
• MMP-1 epitope increased interleukin 4 (IL-4) production of rheumatoid arthritis lymphocytes and decreased IL-4 production by control lymphocytes (PMID:12784383)
• These data provide evidence that tissue factor pathway inhibitor-2 does not bind to matrix metalloproteinases-2, -9 or -1, or regulate matrix metalloproteinase-1, in the extracellular matrix. (PMID:12787920)
• Hypoxia may be responsible for delayed wound healing by inducing an increase of MMP-1 synthesis. (PMID:12788533)
• MMP1 is a senescence-associated gene in normal human oral keratinocytes. (PMID:12837283)
• A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with renal cell carcinoma (PMID:12845675)
• study showed no change in metalloproteinase-1 production in response to varying estrogen levels in fibroblasts that were derived from incontinent women (PMID:12861139)
• Patients with deteriorating heart failure have increased expression of TIMP1 and MMP1 mRNA. Correlation with pro-inflammatory cytokines suggests common pathways of regulation and potential activation by IL-6 and IL1-beta. (PMID:12873541)
• Upregulation of mmp-1 ia assiciated with neoplasm invasiveness in Hereditary nonpolyposis colorectal cancers (PMID:12949792)
• monocyte matrix metalloproteinase-1 and -9 are differentially regulated by interferon gamma through tumor necrosis factor-alpha and caspase 8 (PMID:12960156)
• reported association between the matrix metalloproteinase 1 promoter polymorphism and ovarian cancer risk was not supported by our (PMID:12969782)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000012395
danio_rerio		ENSDARG00000108401
danio_rerio		ENSDARG00000114451
mus_musculus	Mmp1b	ENSMUSG00000041620
mus_musculus	Mmp1a	ENSMUSG00000043089
rattus_norvegicus	Mmp1b	ENSRNOG00000008881
rattus_norvegicus	Mmp1	ENSRNOG00000032353
caenorhabditis_elegans		WBGENE00010524
caenorhabditis_elegans		WBGENE00012185
caenorhabditis_elegans		WBGENE00012364
caenorhabditis_elegans		WBGENE00016283
caenorhabditis_elegans		WBGENE00194737

Paralogs (23): MMP25 (ENSG00000008516), MMP2 (ENSG00000087245), MMP11 (ENSG00000099953), MMP9 (ENSG00000100985), MMP15 (ENSG00000102996), HPX (ENSG00000110169), MMP8 (ENSG00000118113), MMP19 (ENSG00000123342), MMP24 (ENSG00000125966), MMP7 (ENSG00000137673), MMP20 (ENSG00000137674), MMP27 (ENSG00000137675), MMP13 (ENSG00000137745), MMP3 (ENSG00000149968), MMP21 (ENSG00000154485), MMP16 (ENSG00000156103), MMP14 (ENSG00000157227), MMP10 (ENSG00000166670), MMP26 (ENSG00000167346), MMP23B (ENSG00000189409), MMP17 (ENSG00000198598), MMP12 (ENSG00000262406), MMP28 (ENSG00000271447)

Protein

Protein identifiers

Interstitial collagenase — P03956 (reviewed: P03956)

Alternative names: Fibroblast collagenase, Matrix metalloproteinase-1

All UniProt accessions (1): P03956

UniProt curated annotations — full annotation on UniProt →

Function. Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat’s mediated neurotoxicity.

Subunit / interactions. (Microbial infection) Interacts with HIV-1 Tat.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Undergoes autolytic cleavage to two major forms (22 kDa and 27 kDa). A minor form (25 kDa) is the glycosylated form of the 22 kDa form. The 27 kDa form has no activity while the 22/25 kDa form can act as activator for collagenase. Tyrosine phosphorylated in platelets by PKDCC/VLK.

Activity regulation. Can be activated without removal of the activation peptide.

Cofactor. Binds 4 Ca(2+) ions per subunit. Binds 2 Zn(2+) ions per subunit.

Domain organisation. There are two distinct domains in this protein; the catalytic N-terminal, and the C-terminal which is involved in substrate specificity and in binding TIMP (tissue inhibitor of metalloproteinases). The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Similarity. Belongs to the peptidase M10A family.

RefSeq proteins (2): NP_001139410, NP_002412* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000585	Hemopexin-like_dom	Domain
IPR001818	Pept_M10_metallopeptidase	Domain
IPR002477	Peptidoglycan-bd-like	Domain
IPR006026	Peptidase_Metallo	Domain
IPR018486	Hemopexin_CS	Conserved_site
IPR018487	Hemopexin-like_repeat	Repeat
IPR021158	Pept_M10A_Zn_BS	Binding_site
IPR021190	Pept_M10A	Family
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR033739	M10A_MMP	Domain
IPR036365	PGBD-like_sf	Homologous_superfamily
IPR036375	Hemopexin-like_dom_sf	Homologous_superfamily

Pfam: PF00045, PF00413, PF01471

Enzyme classification (BRENDA):

• EC 3.4.24.7 — interstitial collagenase (BRENDA: 11 organisms, 121 substrates, 166 inhibitors, 52 Km, 47 kcat entries)

Substrate kinetics (BRENDA)

28 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
COLLAGEN I ALPHA-1 CHAIN	0.0009–0.74	8
COLLAGEN I ALPHA-2 CHAIN	0.0003–0.53	8
HUMAN TYPE I COLLAGEN	0.0005–0.0011	4
HUMAN TYPE III COLLAGEN	0.0013–0.0024	3
ALPHA1(I)772-786 TRIPLE-HELICAL PEPTIDE	0.063–0.2076	2
FTHP-3	0.0612–0.0666	2
HUMAN TYPE II COLLAGEN	0.001–0.0021	2
2,4-DINITROPHENYL-PRO-BETA-CYCLOHEXYL-ALA-GLY-CY	0.013	1
2,4-DINITROPHENYL-PRO-LEU-ALA-LEU-TRP-ALA-ARG-OH	0.026	1
ACETYL-PRO-LEU-GLY-ILE-LEU-GLY-OC2H5	0.0013	1
ACETYL-PRO-LEU-GLY-LEU-LEU-GLY-OC2H5	0.0012	1
ACETYL-PRO-LEU-GLY-SCH[CH2CH(CH3)2CO]-LEU-LEU-OC	0.0039	1
BOVINE TYPE I COLLAGEN	0.0002	1
GLY-PRO-GLN-GLY-ILE-ALA-GLY-GLN-GLN	3.3	1
GLY-PRO-GLN-GLY-ILE-ALA-GLY-GLN-GLN-ARG-GLY-VAL-	0.63	1

UniProt features (103 total): strand 31, binding site 24, helix 10, sequence conflict 7, sequence variant 6, turn 5, repeat 4, chain 3, modified residue 3, site 2, signal peptide 1, propeptide 1, short sequence motif 1, active site 1, glycosylation site 1, disulfide bond 1, mutagenesis site 1, region of interest 1

Structure

Experimental structures (PDB)

15 structures.

PDB	Method	Resolution (Å)
1HFC	X-RAY DIFFRACTION	1.5
1CGE	X-RAY DIFFRACTION	1.9
966C	X-RAY DIFFRACTION	1.9
1CGF	X-RAY DIFFRACTION	2.1
1SU3	X-RAY DIFFRACTION	2.2
2TCL	X-RAY DIFFRACTION	2.2
3SHI	X-RAY DIFFRACTION	2.2
1CGL	X-RAY DIFFRACTION	2.4
2J0T	X-RAY DIFFRACTION	2.54
2CLT	X-RAY DIFFRACTION	2.67
4AUO	X-RAY DIFFRACTION	3
1AYK	SOLUTION NMR
2AYK	SOLUTION NMR
3AYK	SOLUTION NMR
4AYK	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P03956-F1	91.29	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 219; 143 (not glycosylated); 269–270 (cleavage; by autolysis)

Ligand- & substrate-binding residues (24): 92 (in inhibited form); 124; 158; 168; 170; 175; 176; 178; 180; 183; 190; 192 …

Post-translational modifications (3): 57, 274, 360

Disulfide bonds (1): 278–466

Glycosylation sites (1): 120

Mutagenesis-validated functional residues (1):

Position	Phenotype
360	partial reduction of tyrosine phosphorylation in the presence of pkdcc/vlk.

Function

Pathways and Gene Ontology

Reactome pathways

13 pathways

ID	Pathway
R-HSA-1442490	Collagen degradation
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1592389	Activation of Matrix Metalloproteinases
R-HSA-210991	Basigin interactions
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-109582	Hemostasis
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-1474244	Extracellular matrix organization
R-HSA-168256	Immune System
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-392499	Metabolism of proteins
R-HSA-449147	Signaling by Interleukins

MSigDB gene sets: 448 (showing top): MODULE_172, AHRARNT_01, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MODULE_52, MCLACHLAN_DENTAL_CARIES_UP, YAGI_AML_WITH_INV_16_TRANSLOCATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_CELLULAR_RESPONSE_TO_UV, chr11q22, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MODULE_128, SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER, GNF2_PTX3, PID_REG_GR_PATHWAY

GO Biological Process (6): proteolysis (GO:0006508), extracellular matrix disassembly (GO:0022617), extracellular matrix organization (GO:0030198), collagen catabolic process (GO:0030574), positive regulation of protein-containing complex assembly (GO:0031334), cellular response to UV-A (GO:0071492)

GO Molecular Function (8): endopeptidase activity (GO:0004175), metalloendopeptidase activity (GO:0004222), serine-type endopeptidase activity (GO:0004252), peptidase activity (GO:0008233), zinc ion binding (GO:0008270), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (2): extracellular region (GO:0005576), extracellular matrix (GO:0031012)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Degradation of the extracellular matrix	2
Extracellular matrix organization	1
Cell surface interactions at the vascular wall	1
Metabolism of proteins	1
Signaling by Interleukins	1
Immune System	1
Hemostasis	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidase activity	2
endopeptidase activity	2
protein metabolic process	1
cellular component disassembly	1
extracellular matrix organization	1
extracellular structure organization	1
external encapsulating structure organization	1
catabolic process	1
collagen metabolic process	1
regulation of protein-containing complex assembly	1
positive regulation of cellular component biogenesis	1
positive regulation of cellular component organization	1
protein-containing complex assembly	1
cellular response to UV	1
response to UV-A	1
metallopeptidase activity	1
serine-type peptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
transition metal ion binding	1
catalytic activity	1
cation binding	1
cellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

2902 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MMP1	TIMP1	P01033	985
MMP1	TIMP2	P16035	921
MMP1	IL1B	P01584	849
MMP1	F2R	P25116	828
MMP1	PLAU	P00749	822
MMP1	PITRM1	Q5JRX3	801
MMP1	ELN	P15502	796
MMP1	IL1A	P01583	779
MMP1	EGF	P01133	779
MMP1	FN1	P02751	777
MMP1	CCL2	P13500	754
MMP1	TIMP4	Q99727	754
MMP1	ADAMTS3	O15072	751
MMP1	COL1A1	P02452	739
MMP1	IL6	P05231	732

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MMP1	SOX8	psi-mi:“MI:0915”(physical association)	0.370
NEK4	QSOX1	psi-mi:“MI:0914”(association)	0.350
F2R	MMP1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (27): F2R (Co-localization), MMP1 (Co-localization), MMP1 (Affinity Capture-MS), MMP1 (Synthetic Lethality), MMP1 (Reconstituted Complex), MMP1 (Affinity Capture-MS), MMP1 (Reconstituted Complex), BCAN (Biochemical Activity), MMP1 (Affinity Capture-Western), ITGA2 (Affinity Capture-Western), MMP1 (Affinity Capture-MS), MMP1 (Affinity Capture-MS), MMP1 (Affinity Capture-MS), MMP2 (Negative Genetic), MMP24 (Negative Genetic)

ESM2 similar proteins: A0A0C5PRQ1, A0FKN6, C9D7R2, C9D7R3, D2KBH9, D5FM34, D5FM37, K7Z9Q9, O13065, O17264, O35548, O62243, P03956, P07584, P0DJJ2, P0DM62, P31580, P31581, P42662, P42664, P50280, P51512, P55112, P55113, P55114, P91828, P98060, P98061, P98068, P98070, Q10738, Q18206, Q18439, Q20191, Q20459, Q20958, Q21178, Q21181, Q21252, Q22396

Diamond homologs: A4KX75, D0EM77, G5EBU3, O04529, O18733, O18767, O18927, O23507, O55123, O55761, O60882, O62806, O77656, P03956, P03957, P07152, P08253, P08254, P09237, P09238, P13943, P14780, P21692, P22757, P23097, P28862, P28863, P29136, P33434, P33435, P33436, P34960, P39900, P41245, P41246, P45452, P50280, P50281, P50282, P50757

SIGNOR signaling

14 interactions.

A	Effect	B	Mechanism
FBN1	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
MMP1	up-regulates	Angiogenesis
CITED2	“down-regulates quantity by repression”	MMP1	“transcriptional regulation”
MMP1	“down-regulates quantity by destabilization”	COL2A1	cleavage
ZMYND8	“down-regulates quantity by repression”	MMP1	“transcriptional regulation”
MMP1	“up-regulates activity”	HBEGF	cleavage
WNT7A	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
ZNF384	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
MMP1	“down-regulates quantity by destabilization”	COL1A1	cleavage
MMP1	“down-regulates quantity by destabilization”	COL1A2	cleavage
MMP1	“down-regulates quantity by destabilization”	COL3A1	cleavage
MMP1	up-regulates	ECM_disassembly
MMP1	down-regulates	ECM

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

146 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	17
Benign	38

Top pathogenic / likely-pathogenic (0)

SpliceAI

742 predictions. Top by Δscore:

Variant	Effect	Δscore
11:102790697:ACTT:A	donor_loss	1.0000
11:102790699:TTA:T	donor_loss	1.0000
11:102790700:TA:T	donor_loss	1.0000
11:102790701:A:AC	donor_gain	1.0000
11:102790701:AC:A	donor_gain	1.0000
11:102790701:ACCAT:A	donor_gain	1.0000
11:102790702:C:A	donor_loss	1.0000
11:102790702:C:CA	donor_gain	1.0000
11:102790702:CC:C	donor_gain	1.0000
11:102790702:CCA:C	donor_gain	1.0000
11:102790702:CCAT:C	donor_gain	1.0000
11:102790702:CCATC:C	donor_gain	1.0000
11:102790802:CATAC:C	acceptor_gain	1.0000
11:102790803:ATAC:A	acceptor_gain	1.0000
11:102790804:TAC:T	acceptor_gain	1.0000
11:102790805:AC:A	acceptor_gain	1.0000
11:102790806:CC:C	acceptor_gain	1.0000
11:102790807:C:CC	acceptor_gain	1.0000
11:102790812:C:CT	acceptor_gain	1.0000
11:102791328:CTTA:C	donor_loss	1.0000
11:102791329:TTACC:T	donor_loss	1.0000
11:102791330:TACCT:T	donor_loss	1.0000
11:102791331:A:AC	donor_gain	1.0000
11:102791331:A:C	donor_loss	1.0000
11:102791331:ACCT:A	donor_gain	1.0000
11:102791332:C:A	donor_loss	1.0000
11:102791332:C:CC	donor_gain	1.0000
11:102791332:CCT:C	donor_gain	1.0000
11:102791332:CCTC:C	donor_gain	1.0000
11:102791492:TTCC:T	acceptor_gain	1.0000

AlphaMissense

3141 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:102796734:A:C	F185L	0.997
11:102796734:A:T	F185L	0.997
11:102796736:A:G	F185L	0.997
11:102796767:A:C	F174L	0.997
11:102796767:A:T	F174L	0.997
11:102796769:A:G	F174L	0.997
11:102797024:A:C	F163L	0.996
11:102797024:A:T	F163L	0.996
11:102797026:A:G	F163L	0.996
11:102797279:C:A	W109C	0.995
11:102797279:C:G	W109C	0.995
11:102796680:C:A	W203C	0.994
11:102796680:C:G	W203C	0.994
11:102795549:A:C	H228Q	0.993
11:102795549:A:T	H228Q	0.993
11:102795567:A:C	H222Q	0.993
11:102795567:A:T	H222Q	0.993
11:102797092:A:G	W141R	0.993
11:102797092:A:T	W141R	0.993
11:102795479:C:G	D252H	0.992
11:102795569:G:C	H222D	0.992
11:102795581:G:C	H218D	0.992
11:102796682:A:G	W203R	0.992
11:102796682:A:T	W203R	0.992
11:102795525:C:A	M236I	0.991
11:102795525:C:G	M236I	0.991
11:102795525:C:T	M236I	0.991
11:102795559:C:T	G225E	0.991
11:102795576:T:A	E219D	0.991
11:102795576:T:G	E219D	0.991

dbSNP variants (sampled 300 via entrez): RS1000350191 (11:102796292 A>C), RS1000803147 (11:102791440 G>A), RS1000986045 (11:102792025 T>C), RS1001036252 (11:102797883 A>G), RS1001267121 (11:102793484 A>G), RS1001333506 (11:102792254 T>C), RS1001371280 (11:102798928 G>A,T), RS1001424911 (11:102798643 C>G), RS1001718338 (11:102793221 G>A), RS1001927369 (11:102798742 A>G), RS1002422733 (11:102792985 A>C), RS1002987656 (11:102794722 A>G), RS1003092169 (11:102799843 G>A), RS1003175954 (11:102794452 C>A,T), RS1003777678 (11:102790498 T>C)

Disease associations

OMIM: gene MIM:120353 | disease phenotypes: MIM:178500, MIM:226600, MIM:610504

GenCC curated gene-disease

Mondo (4): interstitial lung disease 2 (MONDO:0800497), recessive dystrophic epidermolysis bullosa (MONDO:0009179), COPD, severe early onset (MONDO:0011751), preterm premature rupture of the membranes (MONDO:0012511)

Orphanet (4): Idiopathic pulmonary fibrosis (Orphanet:2032), Acute interstitial pneumonia (Orphanet:79126), Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form (Orphanet:79408), Recessive dystrophic epidermolysis bullosa inversa (Orphanet:79409)

HPO phenotypes

58 total (30 of 58 shown, HPO-id order):

HPO	Term
HP:0000079	Abnormality of the urinary system
HP:0000083	Renal insufficiency
HP:0000099	Glomerulonephritis
HP:0000160	Narrow mouth
HP:0000478	Abnormality of the eye
HP:0000572	Visual loss
HP:0000670	Carious teeth
HP:0000716	Depression
HP:0000739	Anxiety
HP:0000794	IgA deposition in the glomerulus
HP:0000823	Delayed puberty
HP:0000938	Osteopenia
HP:0000939	Osteoporosis
HP:0000982	Palmoplantar keratoderma
HP:0001030	Fragile skin
HP:0001056	Milia
HP:0001057	Aplasia cutis congenita
HP:0001075	Atrophic scars
HP:0001371	Flexion contracture
HP:0001510	Growth delay
HP:0001581	Recurrent skin infections
HP:0001644	Dilated cardiomyopathy
HP:0001798	Anonychia
HP:0001891	Iron deficiency anemia
HP:0001903	Anemia
HP:0001917	Renal amyloidosis
HP:0001965	Abnormal scalp morphology
HP:0002015	Dysphagia
HP:0002020	Gastroesophageal reflux
HP:0002671	Basal cell carcinoma

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006585_1874	Blood protein levels	7.000000e-107
GCST009731_49	Blood protein levels in cardiovascular risk	2.000000e-82

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008193	interstitial collagenase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C563032	Preterm Premature Rupture of the Membranes (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2095216 (PROTEIN FAMILY), CHEMBL2111422 (SELECTIVITY GROUP), CHEMBL332 (SINGLE PROTEIN), CHEMBL4523984 (SELECTIVITY GROUP)

Molecules with ChEMBL bioactivity

21 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 529,513 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1200448	TILUDRONATE DISODIUM	4	5,476
CHEMBL2	PRAZOSIN	4	31,107
CHEMBL421	SULFASALAZINE	4	73,629
CHEMBL481	IRINOTECAN	4	159,900
CHEMBL56367	NIMESULIDE	4	25,455
CHEMBL707	DOXAZOSIN	4	24,931
CHEMBL145	CAFFEIC ACID	3	36,305
CHEMBL279785	MARIMASTAT	3	29,447
CHEMBL297453	EPIGALOCATECHIN GALLATE	3	22,804
CHEMBL50	QUERCETIN	3	74,559
CHEMBL75094	PRINOMASTAT	3	8,839
CHEMBL115653	CIPEMASTAT	2	359
CHEMBL19611	ILOMASTAT	2	12,065
CHEMBL206815	APRATASTAT	2	256
CHEMBL2107228	SOLIMASTAT	2	104
CHEMBL261932	TANOMASTAT	2	1,980
CHEMBL279786	BATIMASTAT	2	21,247
CHEMBL368347	(+)-SECOISOLARICIRESINOL	2	91
CHEMBL440498	CTS-1027	2	615
CHEMBL76222	REBIMASTAT	2	344
CHEMBL87223	AMINOQUINURIDE	2

Clinical evidence (CIViC)

Drug × variant × indication: 1 predictive associations from 1 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
MMP1 Overexpression	Sacituzumab Govitecan	Estrogen-receptor Positive Breast Cancer	Resistance	CIViC D	EID12597

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2071230	MMP1, MMP10		0.00	0
rs7945189	MMP1, MMP10		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M10: Matrix metallopeptidase

Most potent curated ligand interactions (6 total), top 6:

Ligand	Action	Affinity	Parameter
ilomastat	Inhibition	9.25	pIC50
batimastat	Inhibition	9.0	pIC50
cipemastat	Inhibition	8.5	pKi
marimastat	Inhibition	8.3	pIC50
apratastat	Inhibition	7.48	pIC50
CGS-27023A	Inhibition	7.25	pIC50

Binding affinities (BindingDB)

241 measured of 287 human assays (287 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-hydroxy-1-(2-methoxyethyl)-4-[(4-phenoxybenzene)sulfonyl]piperidine-4-carboxamide hydrochloride	KI	0.1 nM
1-Cyclopropyl-N-hydroxy-4-{[4-(phenylthio)phenyl]-sulfonyl}piperidine-4-carboxamide Hydrochloride	KI	0.1 nM
N-hydroxy-2-methyl-2-[(4-phenoxybenzene)sulfonyl]propanamide	KI	0.1 nM
N-Hydroxy-4-{[4-(phenoxyphenyl]sulfonyl}-1- (2-propynyl)4-piperidinecarboxamide, Monohydrochloride	KI	0.13 nM
N-hydroxy-4-{[4-(phenylsulfanyl)benzene]sulfonyl}-1-(prop-2-en-1-yl)piperidine-4-carboxamide hydrochloride	KI	0.15 nM
piperidinyl glycine derivative, 24f	KI	0.19 nM
tert-Butyl 4-[(Hydroxyamino)carbonyl]-4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-1-carboxylate	KI	0.2 nM
N-hydroxy-1-[(3-methoxyphenyl)methyl]-4-{[(4-phenoxybenzene)sulfonyl]methyl}piperidine-4-carboxamide hydrochloride	KI	0.2 nM
tert-butyl 4-(hydroxycarbamoyl)-4-[(4-phenoxybenzene)sulfonyl]piperidine-1-carboxylate	KI	0.2 nM
1-cyclopropyl-N-hydroxy-4-[(4-phenoxybenzene)sulfonyl]piperidine-4-carboxamide hydrochloride	KI	0.2 nM
N-hydroxy-4-[(4-phenoxybenzene)sulfonyl]piperidine-4-carboxamide	KI	0.22 nM
N-hydroxy-4-{[(4-phenoxybenzene)sulfonyl]methyl}-1-(prop-2-yn-1-yl)piperidine-4-carboxamide hydrochloride	KI	0.25 nM
N-Hydroxy-4-{[(4-phenoxyphenyl)sulfonyl]methyl}-1-(2-phenylethyl)piperidine-4-carboxamide Hydrochloride	KI	0.3 nM
N-hydroxy-1-methanesulfonyl-4-[(4-phenoxybenzene)sulfonyl]piperidine-4-carboxamide	KI	0.3 nM
N-hydroxy-1-(2-methoxyethyl)-4-{[4-(phenylsulfanyl)benzene]sulfonyl}piperidine-4-carboxamide hydrochloride	KI	0.3 nM
BOC-piperidinyl glycine derivative, 9	IC50	0.3 nM
N-hydroxy-4-{[4-(phenylsulfanyl)benzene]sulfonyl}-1-(prop-2-yn-1-yl)piperidine-4-carboxamide hydrochloride	KI	0.33 nM
(3R)-N-hydroxy-2-{[4-(4-methoxyphenyl)phenyl]methyl}-1,1-dioxo-1,2-thiazinane-3-carboxamide	KI	0.4 nM
alpha-tetrahydropyran beta-sulfone 1B	KI	0.4 nM
1-acetyl-N-hydroxy-4-{[4-(phenylsulfanyl)benzene]sulfonyl}piperidine-4-carboxamide	KI	0.4 nM
piperidinyl glycine derivative, 24q	IC50	0.4 nM
piperidinyl glycine derivative, 24u	IC50	0.4 nM
N-Hydroxy-1-methyl-4-{[4-(phenylthio)phenyl]sulfonyl}-piperidine-4-carboxamide Hydrochloride	KI	0.5 nM
piperidinyl glycine derivative, 24t	IC50	0.5 nM
Trocade	KI	0.53 nM
piperidinyl glycine derivative, 24d	IC50	0.6 nM
piperidinyl glycine derivative, 24p	IC50	0.6 nM
piperidinyl glycine derivative, 24s	IC50	0.6 nM
N-Pentafluorophenylsulfonyl-N-4-nitrobenzyl-glycine hydroxamate	KI	0.7 nM
N-hydroxy-2-{(4-nitrophenyl)methylsulfonamido}propanamide	KI	0.7 nM
piperidinyl glycine derivative, 27c	IC50	0.7 nM
piperidinyl glycine derivative, 27d	IC50	0.7 nM
BOC-piperidinyl glycine derivative, 22a	IC50	0.75 nM
2-[benzyl(2,3,4,5,6-pentafluorobenzene)sulfonamido]-N-hydroxy-3-methylbutanamide	KI	0.8 nM
2-[benzyl(2,3,4,5,6-pentafluorobenzene)sulfonamido]-N-hydroxy-4-methylpentanamide	KI	0.8 nM
N-hydroxy-2-{(2-nitrophenyl)methylsulfonamido}propanamide	KI	0.8 nM
1-ethyl-N-hydroxy-4-{[4-(phenylsulfanyl)benzene]sulfonyl}piperidine-4-carboxamide hydrochloride	KI	0.8 nM
piperidinyl glycine derivative, 24g	IC50	0.8 nM
piperidinyl glycine derivative, 24o	IC50	0.8 nM
piperidinyl glycine derivative, 25c	IC50	0.8 nM
2-[benzyl(2,3,4,5,6-pentafluorobenzene)sulfonamido]-N-hydroxypropanamide	KI	0.9 nM
4-({[4-(3,4-Dimethylphenoxy)phenyl]sulfonyl}methyl)-N-hydroxy-1-prop-2-ynylpiperidine-4-carboxamide Hydrochloride	KI	0.9 nM
piperidinyl glycine derivative, 24i	IC50	0.9 nM
piperidinyl glycine derivative, 24r	IC50	0.9 nM
piperidinyl glycine derivative, 26d	IC50	0.9 nM
(3R)-N-hydroxy-1,1-dioxo-2-{[4-(pyridin-4-yl)phenyl]methyl}-1,2-thiazinane-3-carboxamide	KI	1 nM
piperidinyl glycine derivative, 24n	IC50	1 nM
(R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide	IC50	1 nM	US-9487462: Inhibitors of matrix metalloproteinases
piperidinyl glycine derivative, 27b	IC50	1.2 nM
piperidinyl glycine derivative, 24a	IC50	1.3 nM

ChEMBL bioactivities

2751 potent at pChembl≥5 of 3190 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	Ki	0.1	nM	CHEMBL281795
10.00	EC50	0.1	nM	CHEMBL526566
9.70	IC50	0.2	nM	ILOMASTAT
9.59	IC50	0.26	nM	CHEMBL321180
9.52	Ki	0.3	nM	CIPEMASTAT
9.52	IC50	0.3	nM	CHEMBL279078
9.40	IC50	0.4	nM	CHEMBL4088630
9.40	Ki	0.4	nM	ILOMASTAT
9.40	IC50	0.4	nM	ILOMASTAT
9.40	IC50	0.4	nM	BATIMASTAT
9.40	IC50	0.4	nM	CHEMBL141080
9.30	Ki	0.5	nM	BATIMASTAT
9.30	IC50	0.5	nM	ILOMASTAT
9.30	IC50	0.5	nM	CHEMBL74670
9.30	IC50	0.5	nM	CHEMBL139886
9.25	IC50	0.56	nM	ILOMASTAT
9.22	Ki	0.6	nM	CHEMBL353382
9.22	Ki	0.6	nM	CHEMBL433314
9.15	Ki	0.7	nM	CHEMBL382705
9.15	Ki	0.7	nM	CHEMBL208181
9.15	Ki	0.7	nM	MARIMASTAT
9.15	IC50	0.7	nM	CHEMBL140511
9.12	IC50	0.75	nM	BATIMASTAT
9.11	IC50	0.78	nM	MARIMASTAT
9.10	IC50	0.8	nM	CHEMBL140970
9.10	EC50	0.8	nM	CHEMBL526106
9.06	IC50	0.88	nM	CHEMBL144611
9.06	Ki	0.87	nM	CHEMBL417537
9.01	Ki	0.97	nM	CHEMBL172885
9.00	Ki	1	nM	CHEMBL30980
9.00	IC50	0.99	nM	BATIMASTAT
9.00	IC50	1	nM	CHEMBL207776
9.00	Ki	1	nM	CHEMBL72511
9.00	Ki	1	nM	CHEMBL324947
9.00	Ki	1	nM	CHEMBL114458
9.00	Ki	1	nM	CHEMBL389020
9.00	IC50	1	nM	MARIMASTAT
9.00	IC50	1	nM	CHEMBL73763
9.00	IC50	1	nM	CHEMBL344633
9.00	IC50	1	nM	CHEMBL337594
8.96	IC50	1.1	nM	CHEMBL144843
8.96	IC50	1.1	nM	CHEMBL432991
8.96	IC50	1.1	nM	CHEMBL4785595
8.96	Ki	1.1	nM	CHEMBL72511
8.96	Ki	1.1	nM	MARIMASTAT
8.96	IC50	1.1	nM	MARIMASTAT
8.92	IC50	1.2	nM	CHEMBL344759
8.92	Ki	1.2	nM	CHEMBL45631
8.92	IC50	1.2	nM	CHEMBL6572
8.92	IC50	1.2	nM	BATIMASTAT

PubChem BioAssay actives

2553 with measured affinity, of 5328 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N,6-dihydroxy-2-(4-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	731524: Inhibition of MMP1 (unknown origin)	ic50	<0.0001	uM
[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] N-(2,2-dimethylpropyl)carbamate	362585: Inhibition of glucocorticoid-mediated human MMP1 expression in PMA stimulated A549 cells assessed as MMP1 protein level by ELISA	ec50	0.0001	uM
(2R)-N’-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	628300: Inhibition of MMP1	ic50	0.0002	uM
(2S,3R)-N-hydroxy-2-methyl-N’-[(2S)-1-(methylamino)-1-oxo-3-(5,6,7,8-tetrahydronaphthalen-1-yl)propan-2-yl]-3-(2-methylpropyl)butanediamide	108731: Activity against Matrix metalloprotease-1 (MMP-1).	ic50	0.0003	uM
(2S,3R)-N,2-dihydroxy-N’-[(2S)-1-(1H-indol-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-methylpropyl)butanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0003	uM
(2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide	264663: Binding affinity to recombinant MMP1	ki	0.0003	uM
(3S)-N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0004	uM
N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide	1454754: Inhibition of human interstitial recombinant N-terminal MMP1 expressed in Escherichia coli BL21(DE3) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate after 20 to 30 mins by spectrofluorimetric analysis	ic50	0.0004	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide	108731: Activity against Matrix metalloprotease-1 (MMP-1).	ic50	0.0004	uM
(3S)-4-(4-bromo-2-methylphenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0005	uM
(2R,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-(hydroxymethyl)-2-(2-methylpropyl)butanediamide	109221: Inhibitory potency against Matrix metalloprotease-1 (MMP-1)	ki	0.0006	uM
(2R,3R)-N,2-dihydroxy-N’-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-methyl-3-(2-methylpropyl)butanediamide	104557: Binding affinity was evaluated against matrix metalloprotease-1	ki	0.0006	uM
(3S)-4-(4-bromophenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0007	uM
(2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-methylpiperidine-2-carboxamide	264663: Binding affinity to recombinant MMP1	ki	0.0007	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(2-methylpropyl)butanediamide	109221: Inhibitory potency against Matrix metalloprotease-1 (MMP-1)	ki	0.0007	uM
(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(4-methoxyphenyl)-3-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanediamide	264663: Binding affinity to recombinant MMP1	ki	0.0007	uM
[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] N-butan-2-ylcarbamate	362585: Inhibition of glucocorticoid-mediated human MMP1 expression in PMA stimulated A549 cells assessed as MMP1 protein level by ELISA	ec50	0.0008	uM
(3S)-N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0008	uM
(2S,3R)-N-hydroxy-N’-[(2R)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-methyl-3-(2-methylpropyl)butanediamide	109228: Inhibition of MMP-1 (Matrix metalloprotease-1)	ki	0.0009	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-[(1-methyl-2-oxoquinolin-6-yl)methoxy]-2-(2-methylpropyl)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0009	uM
(2R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-[4-(4-methoxyphenoxy)butyl]butanediamide	52368: Inhibitory potency against human fibroblast collagenase, MMP-1	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-7-(1-methylimidazol-4-yl)sulfonyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(3R)-6-cyclohexyl-N-hydroxy-3-[3-(methanesulfonamidomethyl)-1,2,4-oxadiazol-5-yl]hexanamide	349373: Inhibition of MMP1	ki	0.0010	uM
(6S)-N-hydroxy-7-(4-methoxyphenyl)sulfonyl-5,5-dimethyl-1,4,7-oxathiazonane-6-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
(3S)-N-hydroxy-2,2-dimethyl-4-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
(8S,11R,12S)-12-N-hydroxy-8-N-methyl-11-(2-methylpropyl)-2,10-dioxo-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylate	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(7S,8R,11S)-7-N-hydroxy-11-N-methyl-8-(2-methylpropyl)-9-oxo-6-oxa-1,10-diazatricyclo[11.6.1.014,19]icosa-13(20),14,16,18-tetraene-7,11-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(4R,7R,8S)-8-N-hydroxy-4-N-methyl-7-(2-methylpropyl)-6,11-dioxo-9-oxa-2-thia-5,12-diazabicyclo[11.4.0]heptadeca-1(17),13,15-triene-4,8-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2S,11S,12R)-7-(benzenesulfonyl)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(9S,12R,13S)-13-N-hydroxy-9-N,4-dimethyl-12-(2-methylpropyl)-3,11-dioxo-1-oxa-4,10-diazacyclotridecane-9,13-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(8S,11R,12S)-12-N-hydroxy-8-N,3-dimethyl-11-(2-methylpropyl)-2,10-dioxo-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2R)-N’-hydroxy-N-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	108923: Inhibition of matrix metalloprotease-1	ki	0.0010	uM
(3S)-N-hydroxy-2,2-dimethyl-4-(4-prop-2-ynoxyphenyl)sulfonylthiomorpholine-3-carboxamide	261911: Inhibition of MMP1	ic50	0.0010	uM
(3S)-N-hydroxy-6-(methoxymethoxy)-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
2-[ethoxy-(4-fluorophenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	108920: Inhibitory activity against matrix metalloprotease-1 (MMP-1)(recombinant human collagenase-1).	ki	0.0010	uM
(2S,11S,12R)-7-(4-aminophenyl)sulfonyl-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide;hydrochloride	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-(hydroxymethyl)-2-(4-methoxyphenyl)butanediamide	264663: Binding affinity to recombinant MMP1	ki	0.0010	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(quinolin-8-ylsulfonylamino)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0011	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(1H-indol-3-yl)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0011	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-prop-2-enylbutanediamide	1727020: Inhibition of PMA-induced human skin fibroblast derived MMP1 by fluorometric assay	ic50	0.0011	uM
(3R,9aS)-N-hydroxy-2-(4-methoxyphenyl)sulfonyl-5-oxo-3,4,7,8,9,9a-hexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-3-carboxamide	108752: Inhibition of human Matrix metalloprotease-1	ic50	0.0012	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(quinolin-6-ylsulfonylamino)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0012	uM
(3S)-4-(4-bromophenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0012	uM
(6S,7R,10S)-6-N-hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0012	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(1H-indol-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0012	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-[(4-oxo-3H-quinazolin-6-yl)sulfonylamino]butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0013	uM
(2S,3R)-N-hydroxy-2-methyl-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	108735: Inhibition of matrix metalloprotease-1 (MMP-1)	ic50	0.0013	uM

CTD chemical–gene interactions

315 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	affects response to substance, affects binding, decreases reaction, increases expression, affects reaction (+6 more)	25
sodium arsenite	increases reaction, affects expression, decreases expression, affects cotreatment, increases abundance (+1 more)	14
Tobacco Smoke Pollution	decreases reaction, increases expression, affects reaction, affects expression, decreases secretion (+1 more)	13
Tetrachlorodibenzodioxin	affects reaction, affects binding, decreases reaction, increases expression, increases activity (+1 more)	12
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	decreases activity, decreases expression, decreases reaction, increases activity, increases expression (+1 more)	9
Estradiol	decreases reaction, increases expression, affects cotreatment, decreases expression, affects binding (+1 more)	8
Vehicle Emissions	increases expression, increases secretion, affects reaction, increases reaction, decreases reaction (+3 more)	7
Benzo(a)pyrene	affects methylation, increases expression	6
Lipopolysaccharides	affects response to substance, affects cotreatment, decreases expression, increases reaction, decreases reaction (+3 more)	6
U 0126	decreases reaction, increases expression, increases secretion, decreases expression, increases reaction	5
(+)-JQ1 compound	affects cotreatment, decreases expression	5
Acetylcysteine	decreases reaction, increases abundance, increases activity, increases expression	5
Air Pollutants	increases abundance, increases expression, decreases expression, increases secretion, decreases reaction	5
Hydrogen Peroxide	affects expression, decreases expression, decreases reaction, increases expression	5
Quercetin	decreases expression, decreases reaction, increases expression, increases secretion	5
Silicon Dioxide	increases expression, increases reaction	5
cobaltiprotoporphyrin	decreases expression, increases reaction, decreases reaction, increases expression	4
Resveratrol	decreases reaction, increases activity, increases expression, increases secretion	4
Plant Extracts	increases abundance, decreases reaction, increases expression, decreases expression	4
Smoke	decreases nitrosation, increases expression, increases secretion	4
Tetradecanoylphorbol Acetate	increases expression, increases reaction, decreases reaction	4
Cyclosporine	increases expression, decreases expression	4
Cadmium Chloride	decreases expression, decreases reaction, increases expression, increases secretion	4
Simvastatin	decreases secretion, decreases reaction, increases expression, increases secretion, decreases expression	4
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	decreases reaction, increases expression, increases secretion, increases reaction	3
SB 203580	decreases reaction, increases activity, increases expression	3
pyrazolanthrone	decreases reaction, increases activity, increases expression	3
2,2’,4,4’-tetrabromodiphenyl ether	increases expression, increases secretion	3
Arsenic Trioxide	decreases expression, increases secretion, affects cotreatment, decreases activity, decreases secretion (+3 more)	3
Dexamethasone	decreases reaction, increases expression, decreases expression, decreases secretion	3

ChEMBL screening assays

588 unique, capped per target: 574 binding, 10 admet, 3 functional, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4481593	Binding	Inhibition of collagenase (unknown origin) at 200 uM relative to control	Deleting a Chromatin Remodeling Gene Increases the Diversity of Secondary Metabolites Produced by Colletotrichum higginsianum. — J Nat Prod
CHEMBL663111	Functional	In vitro antagonist activity against collagenase induced gel-filtered platelet (GFP) aggregation at 50 uM; NA=Inactive	Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. — J Med Chem
CHEMBL3868398	ADMET	Inhibition of recombinant human AMPA-activated MMP1 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate measured after 40 mins by spectrofluorimetric method	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

6 cell lines: 5 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_AB52	BHK-MMP1	Spontaneously immortalized cell line	Male
CVCL_B8KL	Abcam HCT 116 MMP1 KO	Cancer cell line	Male
CVCL_B8YX	Abcam MCF-7 MMP1 KO	Cancer cell line	Female
CVCL_B9MU	Abcam A-549 MMP1 KO	Cancer cell line	Male
CVCL_E0I7	Ubigene HeLa MMP1 KO	Cancer cell line	Female
CVCL_F1P4	HyCyte HCT 116 KO-hMMP1	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00106821	PHASE4	COMPLETED	Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
NCT00115492	PHASE4	COMPLETED	Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
NCT00132860	PHASE4	UNKNOWN	Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)
NCT00139932	PHASE4	COMPLETED	Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
NCT00144196	PHASE4	COMPLETED	12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00144911	PHASE4	COMPLETED	ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
NCT00152984	PHASE4	COMPLETED	Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00153075	PHASE4	COMPLETED	Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00181207	PHASE4	COMPLETED	Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
NCT00184977	PHASE4	COMPLETED	COPD on Primary Care Treatment (COOPT)
NCT00239408	PHASE4	COMPLETED	Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
NCT00239421	PHASE4	COMPLETED	A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239499	PHASE4	COMPLETED	Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00267917	PHASE4	COMPLETED	Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
NCT00274079	PHASE4	COMPLETED	SPIRIVA in Ususal Care
NCT00291460	PHASE4	UNKNOWN	Inspiratory Muscle Training in Hypercapnic COPD
NCT00346749	PHASE4	TERMINATED	ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
NCT00351676	PHASE4	COMPLETED	Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment
NCT00355342	PHASE4	COMPLETED	Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
NCT00358358	PHASE4	COMPLETED	Chronic Obstructive Pulmonary Disease Endpoints Study
NCT00359788	PHASE4	COMPLETED	A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
NCT00361959	PHASE4	COMPLETED	SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
NCT00388882	PHASE4	COMPLETED	Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
NCT00394485	PHASE4	TERMINATED	Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients
NCT00412204	PHASE4	COMPLETED	Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise
NCT00440245	PHASE4	COMPLETED	Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
NCT00523991	PHASE4	COMPLETED	Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
NCT00525512	PHASE4	COMPLETED	Tiotropium In Exercise
NCT00527826	PHASE4	COMPLETED	Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
NCT00530842	PHASE4	COMPLETED	Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00563381	PHASE4	COMPLETED	Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
NCT00569270	PHASE4	COMPLETED	Dynamic Hyperinflation and Tiotropium
NCT00578968	PHASE4	COMPLETED	Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
NCT00592033	PHASE4	COMPLETED	Effect of Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise
NCT00633217	PHASE4	COMPLETED	Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
NCT00633776	PHASE4	WITHDRAWN	Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
NCT00667797	PHASE4	COMPLETED	Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT00680056	PHASE4	COMPLETED	Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
NCT00680641	PHASE4	UNKNOWN	Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)
NCT00720226	PHASE4	COMPLETED	Efficacy of Losartan in Preventing Progression of COPD